MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has announced the development of AI-powered fatigue recognition technology that analyzes voice patterns and is intended to be added as a commercial feature to the company’s Edge AI Intoxication Detection Kiosks. Designed for high-risk industries including aviation, road transport and mining, the fatigue detection module complements MindBio’s broader voice-based diagnostics platform aimed at identifying intoxication and neurological impairment. Initial commercial testing of the kiosk platform is expected in late second quarter 2026.
According to the press release, the AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement. The addition of fatigue detection expands the platform's capabilities to address another critical safety concern in these sectors.
MindBio Therapeutics is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The fatigue detection technology represents a significant step forward in workplace safety, potentially reducing accidents caused by impaired or fatigued workers. The implications of this announcement are far-reaching, as fatigue is a major factor in transportation and industrial accidents, and current detection methods often rely on subjective assessments or invasive tests.
For more information, the full press release is available at https://nnw.fm/WWgcb. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://nnw.fm/MBQIF.
